Inhaled RLF-100 for the Treatment of Severe COVID-19 without respiratory failure

Date Added
December 14th, 2021
PRO Number
Pro00117349
Researcher
John Tejada

List of Studies

Keywords
COVID-19, Coronavirus
Summary

NeuroRx is a study of Inhaled RLF-100 for the treatment of severe COVID-19 without respiratory failure. The objective is to demonstrate the safety and efficacy of the inhaled RLF-100 in preventing progression from severe to critical covid-19. This is an inhaled treatment given three times daily for 7 days.

Institution
Self Regional
Recruitment Contact
Erin Wallace
864-323-6866
erin.smith@selfregional.org

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

Date Added
July 6th, 2021
PRO Number
Pro00111013
Researcher
Leslie Lenert

List of Studies